01
Pipeline Discovery
We map your full asset portfolio, active trials, regulatory milestones, and funding sources — then build the cost structure around your actual business, not a generic pharma template.
Built for Pharmaceutical & Life Sciences Companies
The FDA Doesn't Wait. Neither Does Our AI.
Conscious Accounting combines pharmaceutical-grade financial
expertise with real-time AI to give pharma groups the cost visibility,
regulatory spend tracking, and strategic financial intelligence to
move drugs from pipeline to market — without running out of
runway or answers.
Small Businesses Served
0
+
Years Combined Experience
0
+
Client Retention Rate
0
%
AI Financial Monitoring
0
/7
Integrated with the systems pharma companies rely on
QUICKBOOKS
SAGE INTACCT
NETSUITE
VEEVA
BILL.COM
CARTA
// The Problem
Pharma Finance Is Unlike Any Other Industry on Earth
R&D that spans years. Regulatory spend that’s impossible to predict.
Clinical trials that blow through budgets. Most accounting firms have
never seen the inside of a pharma P&L — and it shows.
01 — R&D COSTS
You Don't Know If You're Actually Profitable
Contingency delays, slow-paying clients, and partner draws create a gap between billed revenue and actual cash on hand. Most firms can’t answer “are we profitable?” without waiting 30 days for a report.
02 — RUNWAY
You're Managing Cash Runway With a Spreadsheet Built Two Rounds Ago
Your burn rate model was built during your Series B. It doesn’t account for the
new trial arm, the FDA delay, or the manufacturing partnership you signed last
quarter. Your investors are asking questions your model can’t answer.
03 — TAX CREDITS
You're Leaving R&D Tax Credits on the Table Every Year
Section 41 R&D tax credits can return 6–8% of qualified research expenses as
a direct tax reduction. Most pharma companies are either claiming them
incorrectly, under-claiming by failing to capture all qualifying costs, or not
claiming them at all.
04 — MULTI-ENTITY
Your IP Holding Structure Is Creating Tax Exposure You Don't Know About
Most pharma groups operate with IP in one entity, operations in another, and
manufacturing in a third — often across jurisdictions. Without proper transfer
pricing documentation, you’re exposed to IRS and international regulatory
scrutiny that can dwarf your entire R&D budget.
05 — CLINICAL TRIALS
Clinical Trial Budgets Blow Out Before Finance Even Knows
Protocol amendments, site activation delays, enrollment shortfalls, and
unblinding costs hit your trial budget without warning. By the time your
accounting team reconciles the CRO invoices, you’re three months past the
point where you could have course-corrected.
06 — AUDIT READINESS
Your Books Aren't Ready for the Scrutiny That Comes With Growth
Pre-revenue pharma companies face a unique moment: the financial standards
acceptable during seed and Series A become liabilities at Series C, partnership
deals, and IPO. Revenue recognition for milestone payments, grant accounting,
and clinical accruals are audit minefields most firms don’t anticipate.
// The Platform
AI That Moves at the Speed of Science
We pair pharmaceutical financial expertise with an always-on AI layer
that tracks every dollar by program, flags runway risk before it becomes
a crisis, and keeps your books ready for the scrutiny your growth will
bring.
⚡ Always On
Real-Time Pharma Intelligence Dashboard
Your company’s live financial pulse — cash runway by program, R&D spend vs. budget by trial, regulatory fee obligations,
and burn rate trajectory — updated in real time. Connected directly to your accounting system. Know your runway to the day,
not the quarter.
Pharma Intelligence Dashboard
- Live
Cash Runway (Current Burn)
18.4 months ✓
Phase II Trial Spend vs. Budget
94% utilized — 6 months remaining
R&D Tax Credit (QRE YTD)
$1.2M qualified — on track
CRO Invoice Accrual Variance
$182K unreconciled ⚠
PDUFA Fee Obligation (Q3)
Reserved ✓
AI Alert: Protocol amendment cost impact
Est. $340K — model updated
Program-Level
R&D Cost Tracking by Program & Trial
We build and maintain a program-level cost structure that maps every dollar — CRO contracts, investigator fees, IND-
enabling studies, regulatory submissions — to the specific asset and stage. When your board asks what Phase II cost,
you have the answer in seconds, not weeks.
Runway Intelligence
Dynamic Cash Runway & Burn Rate Forecasting
An AI-powered runway model that updates in real time as trial costs, milestone payments, and headcount change. When
your operating partner asks “how does the new protocol amendment affect our runway to IND filing?”, you have a board-
ready answer within hours — not a two-week modeling exercise.
Tax Intelligence
R&D Tax Credit Maximization — Section 41
Our AI continuously identifies and documents qualifying research expenses — scientist wages, CRO spend, supply costs,
contract research — to ensure you capture every dollar of your Section 41 credit. Most pharma companies we onboard
discover they’ve been under-claiming by 20–40%.
Compliance
Audit-Ready Books for Every Stage of Growth
We maintain your financials to the standard your next milestone demands — whether that’s a Series C raise, a pharma
partnership deal, or an IPO. Revenue recognition for milestone payments, grant accounting under ASC 958, and clinical
trial accrual methodology built to hold up under the toughest diligence.
// How It Works
Embedded in Your Finance Function in 30 Days
We learn your pipeline. We build your infrastructure. You focus on the
science.
02
Financial Health Audit
We review your books, R&D cost documentation, tax credit history, and clinical accrual methodology — and deliver a financial health score with specific gaps before you pay us a single dollar.
03
AI Integration
We connect your accounting system, CRO contract management, and trial tracking tools to our intelligence layer. Real-time dashboards, runway forecasting, and automated board reports go live within 30 days.
04
Ongoing Partnership
Monthly close support, R&D tax credit documentation, investor reporting, and a team that grows with your pipeline — from IND-enabling studies through NDA submission and beyond.
// The Team
Science-Fluent. Financially Precise.
Our team combines CPAs, life sciences financial specialists, R&D tax
credit experts, and technology engineers who understand the unique
financial architecture of pharmaceutical development — from IND to
NDA.
Nicole Butler-Davis
Founder & Lead CPA
CPA with 20+ years of experience including life sciences and
pharma financial advisory. Expert in R&D cost structures, clinical
accrual methodology, and audit-ready financial frameworks for pre-
revenue and commercial-stage companies.
Matt Heim
Director of AI & Technology
Led financial systems implementations at pharma and biotech
companies from seed through IPO. Expert in integrating clinical trial
management systems, CRO contract tracking, and ERP platforms
into unified real-time financial intelligence layers.
JW D.
R&D Tax & Compliance Specialist
15 years specializing in Section 41 R&D tax credit documentation for
pharma and biotech clients. Has recovered over $40M in previously
unclaimed or under-claimed R&D credits. Expert in multi-entity
transfer pricing and international IP structuring for pharma groups.
Alix M., CPA
Tax Team Lead
Former Big 4 advisor. Specializes in law firm growth strategy, partner buy-in/buy-out structures, and multi-location financial modeling for firms scaling from 1 to 3+ offices.
// How We Compare
The FDA Has Standards. So Do We.
Conscious Accounting
Local CPA
Big 4 / Regional
Real-time R&D spend tracking by program & trial
Dynamic cash runway & burn rate forecasting
Enterprise only
Credit union / community bank specific expertise
Basic only
AI-powered CECL & loan loss modeling
Project basis
Milestone revenue recognition (ASC 606) expertise
Rarely
Transfer pricing & IP holding structure compliance
Separate engagement
Accessible for pre-revenue & early commercial stage
100% money-back guarantee
// Client Voices
What Pharma Leaders Are Saying
From CEOs to CFOs to board chairs — here’s what institutions
// Follow the Conversation
Stay Connected. Stay Ahead.
Weekly insights for pharma CFOs, scientific founders, and life
sciences finance leaders on R&D cost strategy and regulatory finance.
Behind-the-scenes of our team, client wins, and financial education content.
ConsciousAccountingCPA
Community for financial institution leaders navigating growth,
compliance, and strategy.
Blog & Insights
Community for financial institution leaders navigating growth,
compliance, and strategy.
// Follow the Conversation
Ready to Run Your Pipeline With Financial Precision?
Start with a free R&D financial assessment. We’ll show you
exactly what you’re missing — in credits, in visibility, and in audit
readiness — before you pay us a single dollar.
Phone
Offices
Atlanta · Knoxville · St. Petersburg
Hours
Mon–Thu 9AM–5PM · Fri 9AM–1PM